Life Sciences Consonance - 23 Nov 2020 Form 4/A - Amendment Insider Report for Consonance-HFW Acquisition Corp. (SRZN)

Role
Director
Signature
/s/ Kevin Livingston, Manager of Consonance Life Sciences, LLC
Issuer symbol
SRZN
Transactions as of
23 Nov 2020
Net transactions value
+$24,175
Form type
4/A - Amendment
Filing time
19 May 2021, 18:32:27 UTC
Date Of Original Report
25 Nov 2020
Previous filing
19 May 2021
Next filing
19 May 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRZN Class B Ordinary Shares Award $25,156 +3,593,750 $0.007000* 3,593,750 04 Sep 2020 Direct F6
transaction SRZN Class B Ordinary Shares Disposed to Issuer $0 -718,750 -20% $0.000000 2,875,000 08 Oct 2020 Direct F6, F7
transaction SRZN Class B Ordinary Shares Disposed to Issuer $0 -575,000 -20% $0.000000 2,300,000 10 Nov 2020 Direct F6, F7
transaction SRZN Class B Ordinary Shares Sale $327 -30,000 -1.3% $0.0109* 2,270,000 18 Nov 2020 Direct F6
transaction SRZN Class B Ordinary Shares Sale $327 -30,000 -1.3% $0.0109* 2,240,000 18 Nov 2020 Direct F6
transaction SRZN Class B Ordinary Shares Sale $327 -30,000 -1.3% $0.0109* 2,210,000 18 Nov 2020 Direct F6
transaction SRZN Class A Ordinary Shares Award +410,000 410,000 23 Nov 2020 Direct F1, F2, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRZN Warrant Award +136,667 136,667 23 Nov 2020 Class A Ordinary Shares 136,667 $11.50 Direct F1, F2, F3, F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes securities underlying the 410,000 private placement units of the Issuer purchased by the Reporting Person for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at $11.50 per share.
F2 The Reporting Person is the record holder of the shares and warrants reported herein. The Reporting Person is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston have voting and investment discretion over the shares held by the Reporting Person and may be deemed to have shared beneficial ownership of the shares held by the Reporting Person. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
F3 The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering.
F4 The warrants will expire five years after the completion of the Issuer's initial business combination.
F5 Includes 136,667 warrants underlying the units referred to in footnote 1.
F6 This Form 4 amendment is being filed to correct the original Form 4 filed on November 25, 2020. The original Form 4 had the incorrect transaction code, and did not include reporting of all of the required transactions.
F7 The Sponsor contributed these shares back to the Issuer for no consideration.

Remarks:

Consonance Life Sciences, LLC ("Consonance Life Sciences") is governed by a board of managers consisting of Mitchell Blutt, Benny Soffer and Kevin Livingston. Dr. Blutt is the Chairman of the Board of Directors (the "Board") of Consonance-HFW Acquisition Corp. (the "Issuer"). By virtue of its representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Consonance Life Sciences is deemed a director by deputization of the Issuer.